3313. Package # 191.3 (PCR. Genetics. Thrombophilia. Habitual miscarriage)

A comprehensive genetic test designed to identify the main genetic components of thrombophilia associated with impaired fetoplacental blood flow and recurrent pregnancy loss. The panel includes genes most commonly associated with thrombosis, microcirculatory disorders, fetal hypoxia, and preeclampsia.

Thrombophilia is an inherited or acquired predisposition to thrombosis resulting from an imbalance between coagulation and fibrinolysis.

In women with mutations in the F2 (prothrombin), F5 (Factor V Leiden), PAI-1 (SERPINE1), and ITGB3 (β-integrin) genes, the risk of:

• placental vessel thrombosis;
• fetal growth restriction (FGR);
• fetoplacental insufficiency;
• preeclampsia and gestosis;
• placental abruption;
• antenatal fetal death;
• recurrent pregnancy loss (two or more pregnancy losses).

Mutations in PAI-1 reduce fibrinolytic activity, while ITGB3 mutations impair platelet function. In combination with mutations in F2 and F5, these changes form an unfavorable profile for pregnancy outcomes.

Indications for Use:

• Recurrent pregnancy loss (2 or more pregnancy losses).
• A history of pregnancy complications (preeclampsia, placental abruption, fetal growth restriction).
• Fertility problems or failed IVF attempts.
• Preconception assessment in women with a family history of thrombosis.
• Fetal loss at any stage of pregnancy of unknown etiology.
• Arterial or venous thrombosis, pulmonary embolism (PE), or ischemic stroke at a young age.

Recommended for:

• Women of reproductive age with a history of pregnancy loss.
• Patients planning IVF or experiencing implantation difficulties.
• Individuals with thromboembolic complications associated with pregnancy or hormone therapy.
• Relatives of patients with identified thrombophilia mutations.

• Venous blood

In order to exclude factors that may affect the test results, we recommend to follow the preparation rules: